Novo-Nordisk stock: Citi cuts target for Novo-Nordisk stock to DKK 296

Published on 10/16/2026 at 17:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Operating profit reached DKK 27.06 billion for the second quarter of 2026. Novo-Nordisk stock costs EUR 34.83 on October 16, 2026, below its EUR 53.46 high.

Analyst view and valuation

On October 9, 2026, Citi cut its Novo-Nordisk target to DKK 296 from DKK 310.
Operating profit reached DKK 27.06 billion in the second quarter of 2026.
Novo-Nordisk stock costs EUR 34.83 at Lang & Schwarz on October 16, 2026 at 5:13 p.m. CEST, 34.85 percent below the 52-week high of EUR 53.46.
Novo Nordisk trades at a P/E ratio of 9.82, with results scheduled for November 4, 2026.

Isometrisches 3D-Diorama Pharma-Reinraum mit Abfüllanlage, Low-Poly-Stil — Novo Nordisk A/S (DK0062498333): isometrisches Low-Poly-Diorama eines pharmazeutischen Reinraums mit steriler Abfüllanlage, Illustration mit AI erstellt.

Novo-Nordisk (ISIN DK0062498333) carries Citi's DKK 296 price target after the bank cut it from DKK 310 on October 9, 2026, according to Yahoo Finance. The target reflects Citi's view that limited operating-margin expansion could constrain longer-term earnings growth. Operating profit reached DKK 27.06 billion in the second quarter of 2026, according to Earnings Today. The stock was trading at EUR 34.83 at Lang & Schwarz on October 16, 2026 at 5:13 p.m. CEST.

Citi sees limited margin expansion

Citi's revised target followed management commentary that operating margins could remain broadly stable through 2030. The bank lowered its valuation multiple assumption for 2027 earnings to 14 times from 15 times and reduced its earnings-growth estimate for 2027 through 2030 to 9 percent from 12 percent, as Yahoo Finance reported. Citi also raised its near-term adjusted operating-profit forecasts for 2026 and 2027 by 2 to 3 percent.

Second-quarter profit sets the operating base

Novo Nordisk reported DKK 78.49 billion in revenue and DKK 20.99 billion in net income for the quarter ended June 30, 2026. Revenue exceeded the DKK 71.40 billion estimate by 9.90 percent, while adjusted earnings per share of DKK 6.18 exceeded the DKK 5.03 estimate by 22.90 percent, according to Earnings Today. The same quarter produced DKK 55.20 billion in operating cash flow, giving investors a second measure of the company's financial capacity.

Stock sits below its yearly high

The EUR 34.83 Lang & Schwarz price is 34.85 percent below the EUR 53.46 52-week high and above the EUR 30.40 low listed by Borse Express on October 16, 2026. The reported EUR 34.91 market quote on that page places the current euro quotation near the same session level, while the Lang & Schwarz figure remains the article's price.

Valuation and reporting date

Novo Nordisk had a market capitalization of EUR 152.20 billion, a trailing P/E ratio of 9.82 and a dividend yield of 4.55 percent in the October 15, 2026 valuation snapshot from Forecaster. The next financial-results announcement is scheduled for November 4, 2026, according to Earnings Today. That date gives the market a defined checkpoint for testing the balance between sales growth and margin pressure.

Price and investor perspective

The current quotation sits below the yearly high while the latest quarterly figures show DKK 27.06 billion in operating profit and DKK 55.20 billion in operating cash flow. Citi's target revision therefore puts margin development ahead of a simple sales-growth narrative.

Novo-Nordisk was trading at EUR 34.83 at Lang & Schwarz on October 16, 2026 at 5:13 p.m. CEST, 34.85 percent below the 52-week high of EUR 53.46.

The further course of trading is shown by the continuously updated real-time quote of Novo-Nordisk stock.